ALC
Alcon Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-33/100
Last price
63.88
▼ 0.45 (0.70%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
63.58
Prev close
64.33
Day high
64.19
Day low
63.00
Volume
2.39M
Market cap
$30.55B
P/E (TTM)
47.87
52W range
61.84 – 87.64
Day trading desk
Gap from prior close
-1.17%
Prior close 64.33
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
0.84%
63.35 – 63.88
Position in range
100%
Near session high
ATR (14D)
1.02
1.60% of price
Prior day high
64.35
PDH
Prior day low
63.55
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 1.87M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.44%
-5.4%
1M
-10.37%
-11.5%
3M
-5.06%
-9.6%
6M
-15.37%
-33.6%
YTD
-19.82%
-34.1%
1Y
-18.34%
-34.8%
3Y
-18.00%
-100.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ALC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
947.46K
Total on file
Fundamentals
Market cap$30.55B
Enterprise value$34.39B
Revenue (TTM)$10.86B
Gross profit$6.22B
EBITDA$2.40B
Net income$643.00M
EPS (TTM)$1.32
Free cash flow$1.27B
Total cash$1.46B
Total debt$5.30B
Book value / share$44.67
Shares outstanding483.40M
Float481.83M
Short % of float—
Dividend yield0.57%
Beta (5Y)0.73
Valuation & profitability ratios
Trailing P/E47.87
Forward P/E15.94
PEG ratio1.12
Price / sales—
Price / book1.41
EV / revenue3.17
EV / EBITDA14.31
Gross margin57.22%
Operating margin14.63%
Profit margin5.92%
Return on equity2.94%
Return on assets2.80%
Debt / equity24.54
Current ratio2.09
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $10.40B | $9.91B | $9.46B | $8.72B | +4.9% |
| Operating revenue | $10.32B | $9.84B | $9.37B | $8.65B | +4.9% |
| Cost of revenue | $4.66B | $4.40B | $4.21B | $3.97B | +5.8% |
| Gross profit | $5.75B | $5.51B | $5.25B | $4.75B | +4.2% |
| Research & development | $990.00M | $876.00M | $828.00M | $702.00M | +13.0% |
| Selling, general & admin | $3.45B | $3.25B | $3.21B | $3.07B | +6.1% |
| Total operating expense | $4.38B | $4.10B | $4.21B | $4.08B | +7.0% |
| Operating income | $1.36B | $1.41B | $1.04B | $672.00M | -3.8% |
| Net interest income | -$142.00M | -$120.00M | -$155.00M | -$130.00M | -18.3% |
| Pre-tax income | $1.16B | $1.26B | $832.00M | $463.00M | -7.6% |
| Tax provision | $180.00M | $238.00M | -$142.00M | $128.00M | -24.4% |
| Net income | $980.00M | $1.02B | $974.00M | $335.00M | -3.7% |
| Net income to common | $980.00M | $1.02B | $974.00M | $335.00M | -3.7% |
| Basic EPS | 1.99 | 2.06 | 1.98 | 0.68 | -3.4% |
| Diluted EPS | 1.98 | 2.05 | 1.96 | 0.68 | -3.4% |
| EBIT | $1.36B | $1.45B | $1.02B | $597.00M | -5.8% |
| EBITDA | $2.70B | $2.68B | $2.24B | $1.72B | +0.9% |
| Basic shares | 493.20M | 494.40M | 493.00M | 491.40M | -0.2% |
| Diluted shares | 496.20M | 497.50M | 496.50M | 494.40M | -0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | — | $1.68B | $1.09B | $980.00M | $1.57B | — |
| Cash & short-term investments | — | $1.83B | $1.10B | $980.00M | $1.58B | — |
| Accounts receivable | — | $1.85B | $1.89B | $1.77B | $1.59B | — |
| Inventory | $2.39B | $2.27B | $2.32B | $2.11B | — | +5.4% |
| Total current assets | $6.45B | $6.31B | $5.65B | $5.19B | — | +2.2% |
| Property, plant & equipment | — | $4.84B | $4.72B | $4.42B | $4.08B | — |
| Goodwill & intangibles | — | $17.53B | $17.99B | $18.61B | $17.67B | — |
| Total assets | $31.55B | $30.35B | $29.61B | $29.16B | — | +4.0% |
| Total current liabilities | $3.05B | $2.28B | $2.40B | $2.74B | — | +33.8% |
| Current debt | — | $101.00M | $53.00M | $97.00M | $107.00M | — |
| Long-term debt | — | $4.54B | $4.68B | $4.54B | $3.97B | — |
| Total debt | $509.00M | $497.00M | $5.13B | $5.07B | — | +2.4% |
| Total liabilities | $31.55B | $30.35B | $8.99B | $9.49B | — | +4.0% |
| Shareholder equity | $22.01B | $21.53B | $20.62B | $19.68B | — | +2.2% |
| Working capital | $3.40B | $4.03B | $3.25B | $2.46B | — | -15.7% |
| Net tangible assets | $22.01B | $21.53B | $2.64B | $1.06B | — | +2.2% |
| Shares issued | 499.73M | 499.70M | 499.64M | 497.99M | — | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $980.00M | $1.02B | $974.00M | $335.00M | -3.7% |
| Depreciation & amortisation | $1.33B | $1.23B | $1.22B | $1.12B | +8.7% |
| Stock-based compensation | $162.00M | $150.00M | $144.00M | $140.00M | +8.0% |
| Change in working capital | -$240.00M | -$189.00M | -$404.00M | -$522.00M | -27.0% |
| Operating cash flow | $2.27B | $2.08B | $1.39B | $1.22B | +9.3% |
| Capital expenditure | -$663.00M | -$670.00M | -$851.00M | -$745.00M | +1.0% |
| Investing cash flow | -$1.34B | -$1.17B | -$1.09B | -$1.86B | -15.2% |
| Share buybacks | -$676.00M | $0 | $0 | — | — |
| Dividends paid | -$166.00M | -$130.00M | -$116.00M | -$100.00M | -27.7% |
| Financing cash flow | -$1.12B | -$322.00M | -$211.00M | -$8.00M | -247.5% |
| Free cash flow | $1.61B | $1.41B | $537.00M | $472.00M | +14.3% |
| End cash position | $1.53B | $1.68B | $1.09B | $980.00M | -8.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.82B | $2.71B | $2.72B | $2.61B | $2.60B | +4.3% |
| Operating revenue | $2.78B | $2.69B | $2.70B | $2.59B | $2.58B | +3.6% |
| Cost of revenue | $1.15B | $1.18B | $1.20B | $1.16B | $1.21B | -2.8% |
| Gross profit | $1.68B | $1.52B | $1.52B | $1.46B | $1.39B | +9.8% |
| Research & development | $663.00M | $245.00M | $273.00M | $250.00M | $245.00M | +170.6% |
| Selling, general & admin | $964.00M | $882.00M | $901.00M | $865.00M | $870.00M | +9.3% |
| Total operating expense | $1.66B | $1.23B | $1.20B | $1.13B | $1.14B | +35.0% |
| Operating income | $11.00M | $292.00M | $313.00M | $332.00M | $247.00M | -96.2% |
| Net interest income | -$53.00M | -$50.00M | -$7.00M | -$48.00M | -$47.00M | -6.0% |
| Pre-tax income | -$46.00M | $240.00M | $264.00M | $283.00M | $199.00M | -119.2% |
| Tax provision | -$46.00M | $51.00M | $47.00M | $46.00M | $23.00M | -190.2% |
| Net income | $0 | $189.00M | $217.00M | $237.00M | $176.00M | -100.0% |
| Net income to common | $0 | $189.00M | $217.00M | $237.00M | $176.00M | -100.0% |
| Basic EPS | 0.00 | 0.39 | 0.44 | 0.48 | 0.36 | -100.0% |
| Diluted EPS | 0.00 | 0.39 | 0.44 | 0.48 | 0.35 | -100.0% |
| EBIT | $7.00M | $292.00M | $317.00M | $334.00M | $250.00M | -97.6% |
| EBITDA | $800.00M | $614.00M | $793.00M | $521.00M | $612.00M | +30.3% |
| Basic shares | 486.70M | 487.20M | 489.30M | 493.20M | 495.20M | -0.1% |
| Diluted shares | 488.70M | 490.20M | 492.30M | 495.90M | 497.90M | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.35B | $1.58B | — | $1.50B | $1.41B | $1.41B | -14.1% |
| Cash & short-term investments | $1.46B | $1.66B | — | $1.50B | $1.41B | $1.41B | -12.2% |
| Accounts receivable | $2.08B | $1.98B | — | $1.91B | $1.99B | $1.83B | +4.9% |
| Inventory | $2.51B | $2.44B | $2.39B | $2.43B | $2.39B | — | +3.0% |
| Total current assets | $6.62B | $6.62B | $6.45B | $6.33B | $6.31B | — | +0.1% |
| Property, plant & equipment | $5.26B | $5.22B | — | $5.15B | $5.08B | $4.90B | +0.7% |
| Goodwill & intangibles | $17.53B | $18.14B | — | $18.43B | $18.38B | $18.56B | -3.3% |
| Total assets | $31.10B | $31.62B | $31.55B | $31.52B | $31.39B | — | -1.6% |
| Total current liabilities | $3.17B | $3.00B | $3.05B | $2.99B | $2.42B | — | +5.4% |
| Current debt | $567.00M | $568.00M | — | $568.00M | $71.00M | $104.00M | -0.2% |
| Long-term debt | $4.15B | $4.16B | — | $4.16B | $4.66B | $4.60B | -0.2% |
| Total debt | $5.30B | $5.25B | $509.00M | $5.24B | $5.25B | — | +0.8% |
| Total liabilities | $9.50B | $9.49B | $31.55B | $9.44B | $9.26B | — | +0.2% |
| Shareholder equity | $21.59B | $22.13B | $22.01B | $22.09B | $22.11B | — | -2.4% |
| Working capital | $3.46B | $3.62B | $3.40B | $3.34B | $3.88B | — | -4.4% |
| Net tangible assets | $4.07B | $4.00B | $22.01B | $3.66B | $3.74B | — | +1.8% |
| Shares issued | 483.40M | 499.70M | 499.73M | 499.68M | 500.88M | — | -3.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $0 | $189.00M | $217.00M | $237.00M | $176.00M | -100.0% |
| Depreciation & amortisation | $793.00M | $322.00M | $476.00M | $187.00M | $362.00M | +146.3% |
| Stock-based compensation | $42.00M | $45.00M | $44.00M | $41.00M | $38.00M | -6.7% |
| Change in working capital | -$109.00M | -$243.00M | -$1.00M | $87.00M | -$102.00M | +55.1% |
| Operating cash flow | $510.00M | $418.00M | $658.00M | $724.00M | $505.00M | +22.0% |
| Capital expenditure | -$140.00M | -$191.00M | -$201.00M | -$189.00M | -$133.00M | +26.7% |
| Investing cash flow | -$222.00M | -$218.00M | -$300.00M | -$312.00M | -$154.00M | -1.8% |
| Share buybacks | -$278.00M | -$75.00M | -$307.00M | -$253.00M | -$116.00M | -270.7% |
| Dividends paid | — | — | $0 | $0 | — | — |
| Financing cash flow | -$510.00M | -$133.00M | -$330.00M | -$310.00M | -$383.00M | -283.5% |
| Free cash flow | $370.00M | $227.00M | $457.00M | $535.00M | $372.00M | +63.0% |
| End cash position | $1.35B | $1.58B | $1.53B | $1.50B | $1.41B | -14.1% |
Options analytics
Put / call volume
3.39
Put-heavy session
Put / call open interest
1.03
Positioning, not flow
Max pain
67.50
+6.8% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
103
Contracts, this expiry
Put volume
349
Contracts, this expiry
Heaviest call OI
72.50
231 contracts
Heaviest put OI
65.00
335 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.76 | 0.84 | +11.2% |
| Mar 2026 | 0.82 | 0.85 | +4.1% |
| Dec 2025 | 0.87 | 0.78 | -10.3% |
| Sep 2025 | 0.85 | 0.79 | -7.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.89 | 15 | $2.74B | +5.0% |
| Next quarter | 0.55 | 6 | $2.85B | +4.8% |
| Current year | 3.50 | 24 | $11.09B | +6.6% |
| Next year | 3.97 | 26 | $11.77B | +6.1% |
Analyst targets & ownership
Mean target$83.55
High target$103.00
Low target$62.00
Implied upside30.79%
Analyst count16
ConsensusBUY
Strong buy / Buy4 / 17
Hold5
Sell / Strong sell0 / 1
Held by insiders0.20%
Held by institutions63.53%
Institutions holding1.18K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
64.51
-0.98% from price
SMA 20
65.43
-3.42% from price
SMA 50
69.36
-8.89% from price
SMA 100
68.14
-6.26% from price
SMA 200
73.11
-13.57% from price
EMA 12
64.77
-1.38% from price
EMA 26
66.38
-3.77% from price
EMA 50
67.77
-5.74% from price
RSI (14)
31.5
Neutral
MACD (12,26,9)
-1.61
Hist -0.04
ATR (14)
1.02
1.61% of price
Realised vol 30D
17.9%
Annualised
Bollinger upper
68.12
20, 2σ
Bollinger lower
62.74
20, 2σ
50 / 200 cross
Death
69.36 vs 73.11
Trend bias
Below 200
-13.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.45
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
17.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.9%
Peak to trough
Max drawdown 5Y
-38.4%
Peak to trough
ATR 14
1.02
1.61% of price
Beta (reported)
0.73
5Y monthly, from filing
Short interest
Shares short
17.49M
Prior 11.87M
Change vs prior
+47.4%
Shorts adding
% of float
—
—
% of shares out
3.62%
Against total outstanding
Days to cover
13.0
Crowded exit
Float
481.83M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 26 | Barclays | INITIATED | — | Equal-Weight |
| Sep 22, 26 | Jefferies | MAINTAINED | Buy | Buy |
| Sep 15, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 12, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Aug 12, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Aug 11, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 15, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 8, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| May 7, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| May 7, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 7, 26 | Baird | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate$0.36 / yr
Forward yield0.57%
5-year avg yield0.28%
Payout ratio26.56%
Ex-dividend dateMay 6, 2026
Next pay dateMay 7, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-10
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-15
Corporate Changes & Voting Matters
6-K · 2026-05-05
Corporate Changes & Voting Matters
6-K · 2026-04-02
Corporate Changes & Voting Matters
6-K · 2026-02-24
Corporate Changes & Voting Matters
6-K · 2026-01-07
Proxy Statements
DFAN14A · 2025-12-09
Corporate Changes & Voting Matters
6-K · 2025-11-12
Headlines
Barclays Initiates Coverage on Alcon AG With Equal Weight Rating, $70 Price Target
MT Newswires · 1h ago
Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
Business Wire · 9d ago
Alcon (SWX:ALC) Stock Trades Above Fair Value On Earnings Pressure
Simply Wall St. · 10d ago
Bernstein unveils top European medtech stock picks to buy for H2
Investing.com · 12d ago
Platauro Metals Corp. - Star Project, Utah
TMX Newsfile · 16d ago
STAAR Surgical hires former CEO to lead commercial team
MedTech Dive · 26d ago
Bill Ackman bets AI will make this old-school business stronger
TheStreet · 26d ago
Barron’s Got Cooper Wrong but the Contact-Lens Stock Now Looks Cheap
Barrons.com · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.